<DOC>
	<DOCNO>NCT00424801</DOCNO>
	<brief_summary>The purpose study determine long-term vasodilatory treatment effective standard treatment hypertensive patient microvascular angina pectoris</brief_summary>
	<brief_title>Effects Intensive Long-Term Vasodilation Hypertensive Patients With Microvascular Angina Pectoris</brief_title>
	<detailed_description>Patients hypertension frequently develop angina pectoris . This cause either epicardial stenotic disease , equally frequent , increase resistance small resistance vessel - microvascular dysfunction . This increase resistance cause process call remodelling , exist material vessel wall rearrange around small lumen , whereas sensitivity smooth muscle cell agonist stimulus unchanged . Under rest condition resistance determine tone smooth muscle cell vessel wall structure vessel ( RREST ) . Under hyperemic condition muscle relax resistance determined vessel structure ( RMIN ) . A literature survey various study subject show structural change relate tone rather blood pressure . This suggest resistance vessel structure normalize antihypertensive treatment normalize RREST i.e . rely vasodilatation cause antihypertensive effect reduction cardiac output . The main hypothesis , possible reverse structural change resistance vessel vasodilatory treatment eight month , thereby achieve low coronary peripheral minimal resistance ( determine MRI plethysmography , respectively ) , high work capacity exercise-ECG less tendency angina patient . We include 80 patient essential hypertension , angina pectoris CCS class II-III sign ischemia exercise-ECG myocardial SPECT , without significant stenosis angiography . The patient randomise , parallel , open-label design , either vasodilatory ( lercanidipine , valsartan , doxazosin nicorandil ) standard treatment ( metoprolol , diltiazem isosorbide mononitrate ) . The aim treatment arm BP 120/80 protocol allow add-on therapy reach goal . The patient follow eight month titration period two month . MRI , plethysmography , exercise-ECG echocardiography perform study period . The primary endpoint minimal coronary resistance determine MRI ; secondary endpoint peripheral vascular resistance determine plethysmography , work capacity ischemia threshold exercise-ECG myocardial SPECT .</detailed_description>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Pindolol</mesh_term>
	<mesh_term>Moxonidine</mesh_term>
	<mesh_term>Lercanidipine</mesh_term>
	<mesh_term>Doxazosin</mesh_term>
	<mesh_term>Nicorandil</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Amiloride</mesh_term>
	<criteria>hypertension angina pectoris CCS class IIIV objective sign ischemia exerciseECG myocardial SPECT significant stenosis angiography ( minimal lumen diameter &gt; 50 % relevant reference segment ) know allergy study medication abnormal lab test clinical significance valvular disease haemodynamic significance know secondary hypertension atrial fibrillation significant arrythmias myocardial infarction &lt; 30 day inclusion rest angina &lt; one week inclusion know endocrine disease , nephropathy hepatic disease present malignant disease pregnancy fertile woman use safe contraceptive &gt; 6 month inclusion . Use contraceptives must continue 1 month completion retraction study body mass index &gt; 30 significant chronic obstructive lung disease ( FEV1 &lt; 1.5 l ) participant another study include test medicine present treatment dipyridamole present treatment phosphodiesterase5inhibitors patient want discontinue study period heart transplant patient patient magnetizable metallic implant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
</DOC>